Higher prevalence of coronary microvascular dysfunction in asymptomatic individuals with high levels of lipoprotein(a) with and without heterozygous familial hypercholesterolaemia
(2024) In Atherosclerosis 389.- Abstract
Background and aims: Microvascular dysfunction underlies many cardiovascular disease conditions; little is known regarding its presence in individuals with high levels of lipoprotein(a) [Lp(a)]. The aim of the present study was to determine the frequency of microvascular dysfunction among such subjects with and without concomitant familial hypercholesterolemia (FH). Methods: Four groups of asymptomatic individuals aged 30–59 years, without manifest cardiovascular disease, were recruited (n = 30 per group): controls with Lp(a) < 30 nmol/L, mutation-confirmed FH with Lp(a) < 30 nmol/L, or >125 nmol/L, and individuals with isolated Lp(a) > 125 nmol/L. Participants underwent evaluation of myocardial microvascular function by... (More)
Background and aims: Microvascular dysfunction underlies many cardiovascular disease conditions; little is known regarding its presence in individuals with high levels of lipoprotein(a) [Lp(a)]. The aim of the present study was to determine the frequency of microvascular dysfunction among such subjects with and without concomitant familial hypercholesterolemia (FH). Methods: Four groups of asymptomatic individuals aged 30–59 years, without manifest cardiovascular disease, were recruited (n = 30 per group): controls with Lp(a) < 30 nmol/L, mutation-confirmed FH with Lp(a) < 30 nmol/L, or >125 nmol/L, and individuals with isolated Lp(a) > 125 nmol/L. Participants underwent evaluation of myocardial microvascular function by measuring coronary flow reserve (CFR) using transthoracic Doppler echocardiography, and of peripheral microvascular endothelial function by peripheral arterial tonometry. Results: The groups were balanced in age, sex, and body mass index. Each of the three dyslipoproteinaemic groups had a greater proportion of individuals with impaired coronary flow reserve, 30%, compared to 6.7% of controls (p = 0.014). The median CFR levels did not differ significantly between the four groups, however. Cholesterol-lowering treatment time was longer in the individuals with normal than in those with impaired CFR in the FH + Lp(a) > 125 group (p = 0.023), but not in the group with FH + Lp(a) < 30 (p = 0.468). There was no difference in peripheral endothelial function between the groups. Conclusions: Coronary microvascular dysfunction is more prevalent in asymptomatic individuals with isolated Lp(a) elevation and in heterozygous FH both with and without high Lp(a) compared to healthy controls. Cholesterol-lowering treatment could potentially prevent the development of microvascular dysfunction.
(Less)
- author
- Wodaje, Tigist
; Mahdi, Ali
; Venkateshvaran, Ashwin
LU
; Häbel, Henrike
; Zenlander, Robin
; Gaylard, Benjamin
; Angelin, Bo
; Pernow, John
and Brinck, Jonas
- organization
- publishing date
- 2024-02
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Coronary flow reserve, Endothelial dysfunction, Familial hypercholesterolaemia, lipoprotein(a), Microvascular dysfunction, Reactive hyperaemia index
- in
- Atherosclerosis
- volume
- 389
- article number
- 117439
- publisher
- Elsevier
- external identifiers
-
- scopus:85182379344
- pmid:38219650
- ISSN
- 0021-9150
- DOI
- 10.1016/j.atherosclerosis.2023.117439
- language
- English
- LU publication?
- yes
- id
- 049f72df-e57f-4a5a-b413-276f8a3a9450
- date added to LUP
- 2024-04-11 12:47:49
- date last changed
- 2025-10-14 10:49:33
@article{049f72df-e57f-4a5a-b413-276f8a3a9450,
abstract = {{<p>Background and aims: Microvascular dysfunction underlies many cardiovascular disease conditions; little is known regarding its presence in individuals with high levels of lipoprotein(a) [Lp(a)]. The aim of the present study was to determine the frequency of microvascular dysfunction among such subjects with and without concomitant familial hypercholesterolemia (FH). Methods: Four groups of asymptomatic individuals aged 30–59 years, without manifest cardiovascular disease, were recruited (n = 30 per group): controls with Lp(a) < 30 nmol/L, mutation-confirmed FH with Lp(a) < 30 nmol/L, or >125 nmol/L, and individuals with isolated Lp(a) > 125 nmol/L. Participants underwent evaluation of myocardial microvascular function by measuring coronary flow reserve (CFR) using transthoracic Doppler echocardiography, and of peripheral microvascular endothelial function by peripheral arterial tonometry. Results: The groups were balanced in age, sex, and body mass index. Each of the three dyslipoproteinaemic groups had a greater proportion of individuals with impaired coronary flow reserve, 30%, compared to 6.7% of controls (p = 0.014). The median CFR levels did not differ significantly between the four groups, however. Cholesterol-lowering treatment time was longer in the individuals with normal than in those with impaired CFR in the FH + Lp(a) > 125 group (p = 0.023), but not in the group with FH + Lp(a) < 30 (p = 0.468). There was no difference in peripheral endothelial function between the groups. Conclusions: Coronary microvascular dysfunction is more prevalent in asymptomatic individuals with isolated Lp(a) elevation and in heterozygous FH both with and without high Lp(a) compared to healthy controls. Cholesterol-lowering treatment could potentially prevent the development of microvascular dysfunction.</p>}},
author = {{Wodaje, Tigist and Mahdi, Ali and Venkateshvaran, Ashwin and Häbel, Henrike and Zenlander, Robin and Gaylard, Benjamin and Angelin, Bo and Pernow, John and Brinck, Jonas}},
issn = {{0021-9150}},
keywords = {{Coronary flow reserve; Endothelial dysfunction; Familial hypercholesterolaemia; lipoprotein(a); Microvascular dysfunction; Reactive hyperaemia index}},
language = {{eng}},
publisher = {{Elsevier}},
series = {{Atherosclerosis}},
title = {{Higher prevalence of coronary microvascular dysfunction in asymptomatic individuals with high levels of lipoprotein(a) with and without heterozygous familial hypercholesterolaemia}},
url = {{http://dx.doi.org/10.1016/j.atherosclerosis.2023.117439}},
doi = {{10.1016/j.atherosclerosis.2023.117439}},
volume = {{389}},
year = {{2024}},
}